According to the North American Menopause Society, up to 75% of American women experience hot flashes around menopause. Around 68.5% of women experience vasomotor symptoms (VMS), such as hot flashes and night sweats, as a result of menopause. Although 10% of women continue to have VMS for up to 12 years, the average duration of these symptoms is about 4 years. The market growth is anticipated to be boosted by the rising prevalence of vasomotor and menopausal symptoms, such as hot flashes and night sweats, among women during the menopausal transition.
According to Data Bridge Market Research, the Vasomotor Menopausal Symptoms (VMS) Treatment Market was valued at USD 16.71 billion in 2022, and it would grow up to USD 27.03 billion by 2030..
" Growing menopausal population surge market demand"
The growing menopausal population is a major driver for the VMS treatment market. As women age and reach menopausal age, they are more likely to experience vasomotor symptoms (VMS) such as hot flashes and night sweats. With a larger number of women experiencing these symptoms, there is a higher demand for effective treatment options that can alleviate the discomfort and improve their quality of life. This drives the growth of the VMS treatment market as pharmaceutical companies and healthcare providers strive to meet the increasing demand with innovative and effective treatment solutions.
What restraints the growth of the vasomotor menopausal symptoms (VMS) treatment market?
" Alternative treatment options can impede the market growth”
In the VMS treatment market, alternative treatment options are gaining popularity among women. Many women prefer to explore natural remedies like herbal supplements, lifestyle modifications, and complementary therapies instead of relying solely on conventional pharmaceutical treatments. The availability and increasing acceptance of these alternative options provide women with choices and flexibility in managing their symptoms. This can impact the demand for pharmaceutical VMS treatments as some women opt for alternative approaches that align with their preferences and beliefs regarding healthcare.
Segmentation: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market
The vasomotor menopausal symptoms (VMS) treatment market is segmented on the basis of drug class, route of administration, end-users, and distribution channel
- On the basis of drug class, the vasomotor menopausal symptoms treatment market antidepressants, hormone therapy, anticonvulsant, and others.
- On the basis of route of administration, the vasomotor menopausal symptoms treatment market oral, parenteral, others), end-users (hospitals, specialty clinics, homecare, others.
- On the basis of distribution channel, the vasomotor menopausal symptoms treatment market hospital pharmacy, retail pharmacy, online pharmacy, others
Regional Insights: North America dominates the Global Vasomotor Menopausal Symptoms (VMS) Treatment Market
North America is projected to dominate the VMS treatment market in the forecast period due to several factors. The region boasts a well-developed healthcare infrastructure with advanced medical facilities and a strong network of healthcare providers. This facilitates accessibility to VMS treatment options for women. Additionally, there is high consumer awareness in North America regarding menopause-related health issues, including VMS, leading to a higher demand for effective treatment solutions. The combination of a robust healthcare infrastructure and widespread consumer awareness contributes to North America's dominance in the VMS treatment market.
Asia-Pacific is poised for significant growth in the VMS treatment market due to various factors. The region has a large and growing population, leading to an increasing patient pool of women experiencing menopausal symptoms. Furthermore, there is a rising investment in the healthcare sector, fostering the development and accessibility of VMS treatment options. Governments in the region are also providing support and implementing initiatives to address women's health issues, further driving the market's growth in Asia-Pacific.
To know more about the study, visit, https://www.databridgemarketresearch.com/de/reports/global-vasomotor-menopausal-symptoms-vms-treatment-market
The Prominent Key Players Operating in the Global Vasomotor Menopausal Symptoms (VMS) Treatment Market Include:
- Zhejiang Huahai Pharmaceutical Co., Ltd (China)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Pfizer Inc (U.S.)
- Hikma Pharmaceutical PLC (U.K)
- Amneal Pharmaceuticals LLC. (U.S.)
- Alembic Pharmaceuticals Limited (India)
- Zydus Group (India)
- Dr. Reddy’s Laboratories Ltd (India)
- Abbvie, Inc (U.S.)
- Sun Pharmaceutical Industries Ltd (India)
- Apotex Inc (Canada)
- Aurobindo Pharma (India)
- Endo Pharmaceuticals plc (Ireland)
- Lupin (India)
- Novartis AG (Switzerland)
- WOCKHARDT (India)
Above are the key players covered in the report, to know about more and exhaustive list of vasomotor menopausal symptoms (VMS) treatment market companies contact, https://www.databridgemarketresearch.com/de/contact
Research Methodology: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market
Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by dbmr research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include vendor positioning grid, market time line analysis, market overview and guide, company positioning grid, company market share analysis, standards of measurement, global vs regional and vendor share analysis. Please request analyst call in case of further inquiry.
